TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum tolerated dose of TMLI
Endpoint domain: Adverse events/effects
Primary endpoint: Blood-borne biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ASP1941
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of fever above 40.0 degrees centigrade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neural network engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean heart rate per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute brain water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of pregnancy or live birth
Endpoint domain: Mortality/survival
Primary endpoint: Diabetes-related readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Plasma DTG AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma DTG AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma DTG Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PFDI-20 Prolapse Subscale (POPDI-6) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of ipilimumab treatment after nivolumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of nivolumab treatment after ipilimumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of nivolumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of ipilimumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of interval between nivolumab treatment and ipilimumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Grip Strength (lbs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Key Pinch Strength (lbs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Physician and Patient Rating of Scar Appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aggregated Brief Michigan Hand Questionnaire results (composite score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Static Two Point Discrimination (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportional changes of key metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Molar Angle correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with anti-MEHD7945A antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of baseline Axumin uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HIV-1 Viral Load (Copies/ml) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Either an AIDS-defining Event, a Grade 3 or 4 Adverse Event, or Acute Retroviral Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Viral Set Point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in acetylcholine-induced skin blood flow after hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in sodium nitroprusside-induced skin blood flow after hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in heat-induced skin blood flow after hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in index of microcirculatory resistance under adenosine after hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in index of microcirculatory resistance at rest after hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relative bioavailability of afuresertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major thrombotic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major neurologic complications
Endpoint domain: Adverse events/effects
Primary endpoint: FACBC radiotracer uptake in Head and neck tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute difference between respiratory rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neurocognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Total Knee Replacement Expectations Survey scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of Improvement Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progressive free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate by 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of quetiapine fumarate in combination with an antidepressant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Polycythemia Vera Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Essential Thrombocythemia (ET) Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission without steroids, immunosuppressives and without colectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of APX005M in Stratum 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of APX005M in Stratum 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Concentration of APX005M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of vaccinees demonstrating a take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulmonary index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: brain functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the Plasma Concentration versus Time Curve (AUC) of melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Postoperative Infectious Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: measurement of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety items of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Safety items of SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Safety items of Hematological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in score on the Questionnaire about the Process of Recovery (QPR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in score on the SCORE-15 Index of Family Functioning and Change (SCORE-15)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Oral processing behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2DM remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-Year Relapse-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: 5-Year Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of docetaxel plus carboplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of docetaxel plus carboplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Intraoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change of sleep actigraphy parameters
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Medication Compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in QT/QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Aneurysm Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With 0 to 4 Investigator's Global Assessment Score at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline to Week 6 in Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal Mortality and Morbidity Composite
Endpoint domain: Mortality/survival
Primary endpoint: Geometric Mean Concentration of pneumococcal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serious vaccine related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Direct failure rate of the mixed approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue levels of human beta-defensin 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent change in excess central subfield thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influx constant (Ki) of FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic performance of FDG PET/CT textural indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor muscle tonus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumoral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Motor (EMG) seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Electroencephalography (EEG) seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Gross Motor Function Measure-66 (GMFM-66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety Depression and Mood Scale (ADAMS) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital Recovery Scale on Day 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutritional status 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutritional status 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: routine biomarkers and blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients who collected >= 2 x 10^6 CD34+/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Alaninaminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Obturation of gastric varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of drinks in a typical week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exponential Rate of Change in Serum Potassium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum aerobic capacity (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Different Words (NDW) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Susceptibility to amoxicillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 14 days infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in average daily alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serial determination of troponin I (cTnI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum level of β-amyloid protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum level of S100 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of ARMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Assessment of CVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Assessment of PGZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Clinic Visit Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Patient Activation Measure (PAM-13)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: variability of measurements of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune-reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Control of GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GvL effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of HER2-derived peptide vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the echo-power curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any and Grade 3 Solicited Local Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Solicited General Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression free survival time (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in PTSD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of moderate to severe chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Touch thresholds in the sole of the foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: KD-QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feeling Thermometer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Number of Subjects With Reported Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: The Clinical Global Rating Scale (CGRS) Improvement Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glutathione (GSH) Levels in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Montgomery-Asberg Depression Scale (MADRS) below 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of abnormal laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant change in physical examination and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-ERCP cholangitis
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Grip Strength Measured With Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Gambling Adaptation of Yale-Brown Obsessive Compulsive Scale (PG-Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intensive care unit-acquired infection (ICU-AI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Imatinib-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in the medial prefrontal cortex (MPFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: scores change on the Beck Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: physical and psychological symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative self-thinking scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pharmacokinetics (PK) profile of ARQ 197
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of ARQ 197
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Augmentation of Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Nicardipine administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Nicardipine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in body sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Power of Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Responses (CR) and Partial Responses (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of change in cardiac perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug free urine samples at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-cutaneous Re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of treatment for refractory aGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinician-Administered PTSD-Scale for Children and Adolescents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Ocular Surface Disease Index (OSDI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in questionnaire scores for knowledge, attitudes, and habits regarding a healthy lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in blood concentrations of NT pro-BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aging Male Symptoms score (AMS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Arch Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of wrinkles grade, around the eyes (Crow's feet)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of wrinkles grade of nasolabial folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of skin surface microrelief's regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes